CTLA4 and neoplasm: Subsequent to the clinical success of Ipilimumab, an anti-CTLA4 mAb for the treatment of advanced melanoma which acts by blocking the binding of CTLA-4 expressed on T cells to CD80/86 ligands expressed on tumor cells (Kyi and Postow, 2014), an onslaught of immune checkpoint inhibitors have received accelerated FDA-approval.